{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:40:44Z","timestamp":1788316844593,"version":"build-2803163510"},"reference-count":143,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41584-026-01386-2","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:20:52Z","timestamp":1780050052000},"page":"447-458","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The evolving comorbidity landscape of rheumatoid arthritis"],"prefix":"10.1038","volume":"22","author":[{"given":"Rebecca T.","family":"Brooks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryant R.","family":"England","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7489-3134","authenticated-orcid":false,"given":"Vanessa L.","family":"Kronzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5847-7475","authenticated-orcid":false,"given":"Cynthia S.","family":"Crowson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"1386_CR1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1056\/NEJMra2103726","volume":"388","author":"EM Gravallese","year":"2023","unstructured":"Gravallese, E. M. & Firestein, G. S. Rheumatoid arthritis \u2014 common origins, divergent mechanisms. N. Engl. J. Med. 388, 529\u2013542 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1386_CR2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI178722","volume":"135","author":"AH Abend","year":"2024","unstructured":"Abend, A. H. et al. Estimation of prevalence of autoimmune diseases in the United States using electronic health record data. J. Clin. Invest. 135, e178722 (2024).","journal-title":"J. Clin. Invest."},{"key":"1386_CR3","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1136\/annrheumdis-2019-215920","volume":"78","author":"S Safiri","year":"2019","unstructured":"Safiri, S. et al. Global, regional and national burden of rheumatoid arthritis 1990\u20132017: a systematic analysis of the Global Burden of Disease study 2017. Ann. Rheum. Dis. 78, 1463\u20131471 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1386_CR4","doi-asserted-by":"publisher","first-page":"vi28","DOI":"10.1093\/rheumatology\/kes278","volume":"51","author":"KS Upchurch","year":"2012","unstructured":"Upchurch, K. S. & Kay, J. Evolution of treatment for rheumatoid arthritis. Rheumatology 51, vi28\u2013vi36 (2012).","journal-title":"Rheumatology"},{"key":"1386_CR5","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1093\/rheumatology\/kead106","volume":"62","author":"RJ Black","year":"2023","unstructured":"Black, R. J. et al. Mortality estimates and excess mortality in rheumatoid arthritis. Rheumatology 62, 3576\u20133583 (2023).","journal-title":"Rheumatology"},{"key":"1386_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1136\/annrheumdis-2017-212131","volume":"77","author":"M Holmqvist","year":"2018","unstructured":"Holmqvist, M., Ljung, L. & Askling, J. Mortality following new-onset rheumatoid arthritis: has modern rheumatology had an impact? Ann. Rheum. Dis. 77, 85\u201391 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1386_CR7","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1002\/acr.25053","volume":"75","author":"TM Johnson","year":"2023","unstructured":"Johnson, T. M. et al. A narrowing mortality gap: temporal trends of cause-specific mortality in a national matched cohort study in US veterans with rheumatoid arthritis. Arthritis Care Res. 75, 1648\u20131658 (2023).","journal-title":"Arthritis Care Res."},{"key":"1386_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/acr.23014","volume":"69","author":"E Nikiphorou","year":"2017","unstructured":"Nikiphorou, E. et al. Secular changes in clinical features at presentation of rheumatoid arthritis: increase in comorbidity but improved inflammatory states. Arthritis Care Res. 69, 21\u201327 (2017).","journal-title":"Arthritis Care Res."},{"key":"1386_CR9","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1136\/ard-2023-225093","volume":"83","author":"CS Crowson","year":"2024","unstructured":"Crowson, C. S. et al. Comorbidity clusters in patients with rheumatoid arthritis identify a patient phenotype with a favourable prognosis. Ann. Rheum. Dis. 83, 556\u2013563 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1386_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/acr.24762","volume":"75","author":"BR England","year":"2023","unstructured":"England, B. R. et al. Influence of multimorbidity on new treatment initiation and achieving target disease activity thresholds in active rheumatoid arthritis: a cohort study using the Rheumatology Informatics System for Effectiveness registry. Arthritis Care Res. 75, 231\u2013239 (2023).","journal-title":"Arthritis Care Res."},{"key":"1386_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002022","volume":"8","author":"CS Crowson","year":"2022","unstructured":"Crowson, C. S. et al. Comprehensive assessment of multimorbidity burden in a population-based cohort of patients with rheumatoid arthritis. RMD Open 8, e002022 (2022).","journal-title":"RMD Open"},{"key":"1386_CR12","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.3899\/jrheum.200971","volume":"48","author":"TM Gunderson","year":"2021","unstructured":"Gunderson, T. M., Myasoedova, E., Davis, J. M. III & Crowson, C. S. Multimorbidity burden in rheumatoid arthritis: a population-based cohort study. J. Rheumatol. 48, 1648\u20131654 (2021).","journal-title":"J. Rheumatol."},{"key":"1386_CR13","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrrheum.2013.212","volume":"10","author":"H Radner","year":"2014","unstructured":"Radner, H., Yoshida, K., Smolen, J. S. & Solomon, D. H. Multimorbidity and rheumatic conditions \u2014 enhancing the concept of comorbidity. Nat. Rev. Rheumatol. 10, 252\u2013256 (2014).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1386_CR14","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1136\/annrheumdis-2020-218282","volume":"80","author":"BR England","year":"2021","unstructured":"England, B. R. et al. Burden and trajectory of multimorbidity in rheumatoid arthritis: a matched cohort study from 2006 to 2015. Ann. Rheum. Dis. 80, 286\u2013292 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1386_CR15","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/acr.24956","volume":"75","author":"BR England","year":"2023","unstructured":"England, B. R. et al. Identification of multimorbidity patterns in rheumatoid arthritis through machine learning. Arthritis Care Res. 75, 220\u2013230 (2023).","journal-title":"Arthritis Care Res."},{"key":"1386_CR16","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1093\/rheumatology\/keae670","volume":"64","author":"B Batko","year":"2025","unstructured":"Batko, B. et al. Comorbidity in incident rheumatoid arthritis: a nationwide case\u2013control study with bidirectional follow-up. Rheumatology 64, 3370\u20133378 (2025).","journal-title":"Rheumatology"},{"key":"1386_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/acr.25184","volume":"77","author":"S Dutt","year":"2025","unstructured":"Dutt, S. et al. Multimorbidity patterns and rheumatoid arthritis disease outcomes: findings from a multicenter, prospective cohort. Arthritis Care Res. 77, 337\u2013348 (2025).","journal-title":"Arthritis Care Res."},{"key":"1386_CR18","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41584-024-01154-0","volume":"20","author":"VM Holers","year":"2024","unstructured":"Holers, V. M. et al. Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis. Nat. Rev. Rheumatol. 20, 601\u2013613 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1386_CR19","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/acr.25231","volume":"76","author":"BA Kimbrough","year":"2024","unstructured":"Kimbrough, B. A. et al. Decline in incidence of extra-articular manifestations of rheumatoid arthritis: a population-based cohort study. Arthritis Care Res. 76, 454\u2013462 (2024).","journal-title":"Arthritis Care Res."},{"key":"1386_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ejim.2024.04.026","volume":"126","author":"L Ljung","year":"2024","unstructured":"Ljung, L. et al. Incidence and predisposing factors of extra-articular manifestations in contemporary rheumatoid arthritis. Eur. J. Intern. Med. 126, 95\u2013101 (2024).","journal-title":"Eur. J. Intern. Med."},{"key":"1386_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102735","volume":"20","author":"A Conforti","year":"2021","unstructured":"Conforti, A. et al. Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. Autoimmun. Rev. 20, 102735 (2021).","journal-title":"Autoimmun. Rev."},{"key":"1386_CR22","doi-asserted-by":"publisher","first-page":"7677","DOI":"10.3390\/jcm13247677","volume":"13","author":"JL Rodas Flores","year":"2024","unstructured":"Rodas Flores, J. L. et al. Neutropenia and Felty syndrome in the twenty-first century: redefining ancient concepts in rheumatoid arthritis patients. J. Clin. Med. 13, 7677 (2024).","journal-title":"J. Clin. Med."},{"key":"1386_CR23","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1002\/acr.24856","volume":"74","author":"BF Samhouri","year":"2022","unstructured":"Samhouri, B. F. et al. Incidence, risk factors, and mortality of clinical and subclinical rheumatoid arthritis-associated interstitial lung disease: a population-based cohort. Arthritis Care Res. 74, 2042\u20132049 (2022).","journal-title":"Arthritis Care Res."},{"key":"1386_CR24","doi-asserted-by":"publisher","first-page":"4667","DOI":"10.1093\/rheumatology\/keac208","volume":"61","author":"R Brooks","year":"2022","unstructured":"Brooks, R. et al. The impact of disease severity measures on survival in U.S. veterans with rheumatoid arthritis-associated interstitial lung disease. Rheumatology 61, 4667\u20134677 (2022).","journal-title":"Rheumatology"},{"key":"1386_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152187","volume":"60","author":"HJ Farquhar","year":"2023","unstructured":"Farquhar, H. J. et al. Survival of adults with rheumatoid arthritis associated interstitial lung disease \u2014 a systematic review and meta-analysis. Semin. Arthritis Rheum. 60, 152187 (2023).","journal-title":"Semin. Arthritis Rheum."},{"key":"1386_CR26","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.3899\/jrheum.2024-0252","volume":"51","author":"SA Provan","year":"2024","unstructured":"Provan, S. A. et al. Interstitial lung disease in patients with rheumatoid arthritis or psoriatic arthritis initiating biologics and controls: data from 5 Nordic registries. J. Rheumatol. 51, 1111\u20131118 (2024).","journal-title":"J. Rheumatol."},{"key":"1386_CR27","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.chest.2022.11.035","volume":"163","author":"SM Matson","year":"2023","unstructured":"Matson, S. M. et al. Treatment outcomes for rheumatoid arthritis-associated interstitial lung disease: a real-world, multisite study of the impact of immunosuppression on pulmonary function trajectory. Chest 163, 861\u2013869 (2023).","journal-title":"Chest"},{"key":"1386_CR28","doi-asserted-by":"publisher","first-page":"e166","DOI":"10.1016\/S2665-9913(24)00265-0","volume":"7","author":"BR England","year":"2025","unstructured":"England, B. R. et al. Advanced therapies in US veterans with rheumatoid arthritis-associated interstitial lung disease: a retrospective, active-comparator, new-user, cohort study. Lancet Rheumatol. 7, e166\u2013e177 (2025).","journal-title":"Lancet Rheumatol."},{"key":"1386_CR29","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/art.42075","volume":"74","author":"EL Matteson","year":"2022","unstructured":"Matteson, E. L. et al. Nintedanib in patients with autoimmune disease-related progressive fibrosing interstitial lung diseases: subgroup analysis of the INBUILD trial. Arthritis Rheumatol. 74, 1039\u20131047 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1386_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","volume":"11","author":"JJ Solomon","year":"2023","unstructured":"Solomon, J. J. et al. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Resp. Med. 11, 87\u201396 (2023).","journal-title":"Lancet Resp. Med."},{"key":"1386_CR31","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1056\/NEJMoa2503643","volume":"392","author":"TM Maher","year":"2025","unstructured":"Maher, T. M. et al. Nerandomilast in patients with progressive pulmonary fibrosis. N. Engl. J. Med. 392, 2203\u20132214 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1386_CR32","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/acr.25347","volume":"76","author":"SR Johnson","year":"2024","unstructured":"Johnson, S. R. et al. 2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Care Res. 76, 1070\u20131082 (2024).","journal-title":"Arthritis Care Res."},{"key":"1386_CR33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ard.2025.08.021","volume":"85","author":"KM Antoniou","year":"2026","unstructured":"Antoniou K. M. et al. ERS\/EULAR clinical practice guidelines for connective tissue diseases associated interstitial lung disease. Ann. Rheum. Dis. 85, 22\u201360 (2026).","journal-title":"Ann. Rheum. Dis."},{"key":"1386_CR34","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1016\/S2665-9913(22)00380-0","volume":"5","author":"VL Kronzer","year":"2023","unstructured":"Kronzer, V. L. et al. Autoantibodies against citrullinated and native proteins and prediction of rheumatoid arthritis-associated interstitial lung disease: a nested case\u2013control study. Lancet Rheumatol. 5, e77\u2013e87 (2023).","journal-title":"Lancet Rheumatol."},{"key":"1386_CR35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s41927-024-00389-4","volume":"8","author":"JA Sparks","year":"2024","unstructured":"Sparks, J. A. et al. Design of ANCHOR-RA: a multi-national cross-sectional study on screening for interstitial lung disease in patients with rheumatoid arthritis. BMC Rheumatol. 8, 19 (2024).","journal-title":"BMC Rheumatol."},{"key":"1386_CR36","doi-asserted-by":"publisher","first-page":"e851","DOI":"10.1016\/S2665-9913(25)00158-4","volume":"7","author":"GC McDermott","year":"2025","unstructured":"McDermott, G. C. et al. Risk factors for interstitial lung disease in early rheumatoid arthritis and external validation of screening strategies: a cross-sectional analysis of the prospective SAIL-RA cohort in the USA. Lancet Rheumatol. 7, e851\u2013e863 (2025).","journal-title":"Lancet Rheumatol."},{"key":"1386_CR37","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/acr.25696","volume":"78","author":"M Brink","year":"2026","unstructured":"Brink, M., Wheeler, A., England, B. R. & Rantapaa-Dahlqvist, S. Validation of a genetic risk score combined with clinical variables for predicting pulmonary fibrosis in early rheumatoid arthritis. Arthritis Care Res.78, 696\u2013702 (2026).","journal-title":"Arthritis Care Res."},{"key":"1386_CR38","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/rheumatology\/keae001","volume":"64","author":"AM Wheeler","year":"2025","unstructured":"Wheeler, A. M. et al. Development and internal validation of a clinical and genetic risk score for rheumatoid arthritis-associated interstitial lung disease. Rheumatology 64, 268\u2013275 (2025).","journal-title":"Rheumatology"},{"key":"1386_CR39","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41584-020-0428-y","volume":"16","author":"AG Semb","year":"2020","unstructured":"Semb, A. G., Ikdahl, E., Wibetoe, G., Crowson, C. & Rollefstad, S. Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. Nat. Rev. Rheumatol. 16, 361\u2013379 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1386_CR40","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.3899\/jrheum.200842","volume":"48","author":"E Myasoedova","year":"2021","unstructured":"Myasoedova, E., Davis, J. M., Roger, V. L., Achenbach, S. J. & Crowson, C. S. Improved incidence of cardiovascular disease in patients with incident rheumatoid arthritis in the 2000s: a population-based cohort study. J. Rheumatol. 48, 1379\u20131387 (2021).","journal-title":"J. Rheumatol."},{"key":"1386_CR41","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3899\/jrheum.221170","volume":"50","author":"E Myasoedova","year":"2023","unstructured":"Myasoedova, E. et al. Trends in incidence of chronic heart failure in patients with rheumatoid arthritis: a population-based study validating different heart failure definitions. J. Rheumatol. 50, 881\u2013888 (2023).","journal-title":"J. Rheumatol."},{"key":"1386_CR42","first-page":"505","volume":"59","author":"SA Provan","year":"2020","unstructured":"Provan, S. A. et al. Trends in all-cause and cardiovascular mortality in patients with incident rheumatoid arthritis: a 20-year follow-up matched case\u2013cohort study. Rheumatology 59, 505\u2013512 (2020).","journal-title":"Rheumatology"},{"key":"1386_CR43","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1159\/000514889","volume":"55","author":"K Trommer","year":"2021","unstructured":"Trommer, K., Kostev, K., Jacob, L. & Tanislav, C. Increased incidence of stroke and transient ischemic attack in patients with rheumatoid arthritis and ankylosing spondylitis in Germany. Neuroepidemiology 55, 162\u2013170 (2021).","journal-title":"Neuroepidemiology"},{"key":"1386_CR44","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00296-024-05781-4","volume":"45","author":"M Ausserwinkler","year":"2025","unstructured":"Ausserwinkler, M. et al. Cerebrovascular risk in rheumatoid arthritis patients: insights from carotid artery atherosclerosis in the Paracelsus 10,000 study. Rheumatol. Int. 45, 33 (2025).","journal-title":"Rheumatol. Int."},{"key":"1386_CR45","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1093\/rheumatology\/keaa579","volume":"60","author":"K Yazdani","year":"2021","unstructured":"Yazdani, K. et al. Ten-year risk of cerebrovascular accidents in incident rheumatoid arthritis: a population-based study of trends over time. Rheumatology 60, 2267\u20132276 (2021).","journal-title":"Rheumatology"},{"key":"1386_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1547518","volume":"12","author":"CL Alsing","year":"2025","unstructured":"Alsing, C. L. et al. Trends in stroke occurrence in rheumatoid arthritis: a retrospective cohort study from Western Norway, 1972 through 2020. Front. Med. 12, 1547518 (2025).","journal-title":"Front. Med."},{"key":"1386_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1087571","volume":"14","author":"J Cooper","year":"2023","unstructured":"Cooper, J., Pastorello, Y. & Slevin, M. A meta-analysis investigating the relationship between inflammation in autoimmune disease, elevated CRP, and the risk of dementia. Front. Immunol. 14, 1087571 (2023).","journal-title":"Front. Immunol."},{"key":"1386_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102776","volume":"20","author":"FA Figus","year":"2021","unstructured":"Figus, F. A., Piga, M., Azzolin, I., McConnell, R. & Iagnocco, A. Rheumatoid arthritis: extra-articular manifestations and comorbidities. Autoimmun. Rev. 20, 102776 (2021).","journal-title":"Autoimmun. Rev."},{"key":"1386_CR49","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.semarthrit.2021.06.003","volume":"51","author":"VL Kronzer","year":"2021","unstructured":"Kronzer, V. L. et al. Trends in incidence of dementia among patients with rheumatoid arthritis: a population-based cohort study. Semin. Arthritis Rheum. 51, 853\u2013857 (2021).","journal-title":"Semin. Arthritis Rheum."},{"key":"1386_CR50","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2147\/VHRM.S523939","volume":"21","author":"O Garmish","year":"2025","unstructured":"Garmish, O., Smiyan, S., Hladkykh, F., Koshak, B. & Komorovsky, R. The effects of disease-modifying antirheumatic drugs on cardiovascular risk in inflammatory joint diseases: current evidence and uncertainties. Vasc. Health Risk Manag. 21, 593\u2013605 (2025).","journal-title":"Vasc. Health Risk Manag."},{"key":"1386_CR51","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJMoa1809798","volume":"380","author":"PM Ridker","year":"2019","unstructured":"Ridker, P. M. et al. Low-dose methotrexate for the prevention of atherosclerotic events. N. Engl. J. Med. 380, 752\u2013762 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1386_CR52","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1136\/annrheumdis-2021-220125","volume":"80","author":"TM Johnson","year":"2021","unstructured":"Johnson, T. M. et al. Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis. Ann. Rheum. Dis. 80, 1385\u20131392 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1386_CR53","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/art.41095","volume":"72","author":"JT Giles","year":"2020","unstructured":"Giles, J. T. et al. Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheumatol. 72, 31\u201340 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"1386_CR54","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg, S. R. et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N. Engl. J. Med. 386, 316\u2013326 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1386_CR55","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/ard-2022-222259","volume":"82","author":"C Charles-Schoeman","year":"2023","unstructured":"Charles-Schoeman, C. et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann. Rheum. Dis. 82, 119\u2013129 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1386_CR56","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ard.2025.08.028","volume":"85","author":"JT Giles","year":"2026","unstructured":"Giles J. T. et al. Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease. Ann Rheum Dis. 85, 103\u2013113 (2026).","journal-title":"Ann Rheum Dis."},{"key":"1386_CR57","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1136\/ard-2022-223302","volume":"82","author":"DH Solomon","year":"2023","unstructured":"Solomon, D. H. et al. Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis. Ann. Rheum. Dis. 82, 324\u2013330 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1386_CR58","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(04)16449-0","volume":"363","author":"DW McCarey","year":"2004","unstructured":"McCarey, D. W. et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363, 2015\u20132021 (2004).","journal-title":"Lancet"},{"key":"1386_CR59","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1093\/rheumatology\/kez557","volume":"59","author":"IK Roelsgaard","year":"2020","unstructured":"Roelsgaard, I. K. et al. Smoking cessation is associated with lower disease activity and predicts cardiovascular risk reduction in rheumatoid arthritis patients. Rheumatology 59, 1997\u20132004 (2020).","journal-title":"Rheumatology"},{"key":"1386_CR60","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1002\/acr.25026","volume":"75","author":"L Alfredsson","year":"2023","unstructured":"Alfredsson, L., Klareskog, L. & Hedstrom, A. K. Influence of smoking on disease activity and quality of life in patients with rheumatoid arthritis: results from a Swedish case\u2013control study with longitudinal follow-up. Arthritis Care Res. 75, 1269\u20131277 (2023).","journal-title":"Arthritis Care Res."},{"key":"1386_CR61","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.autrev.2015.06.004","volume":"14","author":"I Hollan","year":"2015","unstructured":"Hollan, I. et al. Prevention of cardiovascular disease in rheumatoid arthritis. Autoimmun. Rev. 14, 952\u2013969 (2015).","journal-title":"Autoimmun. Rev."},{"key":"1386_CR62","first-page":"keaf448","volume":"65","author":"BA Esbensen","year":"2026","unstructured":"Esbensen, B. A. et al. Effect of an intensive smoking cessation intervention on smoking cessation and disease activity in patients with RA: a randomized controlled trial. Rheumatology 65, keaf448 (2026).","journal-title":"Rheumatology"},{"key":"1386_CR63","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/art.41613","volume":"73","author":"B Weber","year":"2021","unstructured":"Weber, B. et al. Divergence of cardiovascular biomarkers of lipids and subclinical myocardial injury among rheumatoid arthritis patients with increased inflammation. Arthritis Rheumatol. 73, 970\u2013979 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1386_CR64","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","volume":"76","author":"R Agca","year":"2017","unstructured":"Agca, R. et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update. Ann. Rheum. Dis. 76, 17\u201328 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1386_CR65","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/rheumatology\/kex038","volume":"56","author":"CS Crowson","year":"2017","unstructured":"Crowson, C. S. et al. Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries. Rheumatology 56, 1102\u20131110 (2017).","journal-title":"Rheumatology"},{"key":"1386_CR66","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy, S. M. et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. J. Am. Coll. Cardiol. 73, e285\u2013e350 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1386_CR67","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1093\/rheumatology\/key105","volume":"57","author":"DH Solomon","year":"2018","unstructured":"Solomon, D. H. et al. The potential benefits of aspirin for primary cardiovascular prevention in rheumatoid arthritis: a secondary analysis of the PRECISION Trial. Rheumatology 57, 1364\u20131369 (2018).","journal-title":"Rheumatology"},{"key":"1386_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100768","volume":"35","author":"M Beydon","year":"2023","unstructured":"Beydon, M. et al. Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study. Lancet Reg. Health Eur. 35, 100768 (2023).","journal-title":"Lancet Reg. Health Eur."},{"key":"1386_CR69","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1002\/ijc.34606","volume":"153","author":"F Wang","year":"2023","unstructured":"Wang, F. et al. Large-scale real-world data analyses of cancer risks among patients with rheumatoid arthritis. Int. J. Cancer 153, 1139\u20131150 (2023).","journal-title":"Int. J. Cancer"},{"key":"1386_CR70","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001241","volume":"6","author":"N Singh","year":"2020","unstructured":"Singh, N. et al. Trends of lymphoma incidence in US veterans with rheumatoid arthritis, 2002\u20132017. RMD Open 6, e001241 (2020).","journal-title":"RMD Open"},{"key":"1386_CR71","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/art.40017","volume":"69","author":"K Hellgren","year":"2017","unstructured":"Hellgren, K. et al. Rheumatoid arthritis and risk of malignant lymphoma: is the risk still increased? Arthritis Rheumatol. 69, 700\u2013708 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"1386_CR72","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1002\/art.42961","volume":"76","author":"RT Brooks","year":"2024","unstructured":"Brooks, R. T. et al. The risk of lung cancer in rheumatoid arthritis and rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 76, 1730\u20131738 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"1386_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1050876","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Cancer risks in rheumatoid arthritis patients who received immunosuppressive therapies: will immunosuppressants work? Front. Immunol. 13, 1050876 (2022).","journal-title":"Front. Immunol."},{"key":"1386_CR74","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.semarthrit.2020.08.007","volume":"50","author":"W Xie","year":"2020","unstructured":"Xie, W. et al. Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: a meta-analysis of observational studies. Semin. Arthritis Rheum. 50, 930\u2013937 (2020).","journal-title":"Semin. Arthritis Rheum."},{"key":"1386_CR75","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1093\/rheumatology\/keab570","volume":"61","author":"V Huss","year":"2022","unstructured":"Huss, V. et al. Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice. Rheumatology 61, 1810\u20131818 (2022).","journal-title":"Rheumatology"},{"key":"1386_CR76","doi-asserted-by":"publisher","first-page":"716","DOI":"10.7326\/0003-4819-151-10-200911170-00008","volume":"151","author":"US Preventive Services Task Force","year":"2009","unstructured":"US Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 151, 716\u2013726 (2009).","journal-title":"Ann. Intern. Med."},{"key":"1386_CR77","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1001\/jama.2018.10897","volume":"320","author":"US Preventive Services Task Force","year":"2018","unstructured":"US Preventive Services Task Force. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA 320, 674\u2013686 (2018).","journal-title":"JAMA"},{"key":"1386_CR78","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1001\/jama.2021.6238","volume":"325","author":"US Preventive Services Task Force","year":"2021","unstructured":"US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA 325, 1965\u20131977 (2021).","journal-title":"JAMA"},{"key":"1386_CR79","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2018.3710","volume":"319","author":"US Preventive Services Task Force","year":"2018","unstructured":"US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA 319, 1901\u20131913 (2018).","journal-title":"JAMA"},{"key":"1386_CR80","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1001\/jama.2021.1117","volume":"325","author":"US Preventive Services Task Force","year":"2021","unstructured":"US Preventive Services Task Force. Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA 325, 962\u2013970 (2021).","journal-title":"JAMA"},{"key":"1386_CR81","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/LGT.0000000000000468","volume":"23","author":"AB Moscicki","year":"2019","unstructured":"Moscicki, A. B. et al. Guidelines for cervical cancer screening in immunosuppressed women without HIV infection. J. Low. Genit. Tract. Dis. 23, 87\u2013101 (2019).","journal-title":"J. Low. Genit. Tract. Dis."},{"key":"1386_CR82","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3899\/jrheum.2025-0190","volume":"52","author":"RT Brooks","year":"2025","unstructured":"Brooks R. T. et al. Cumulative incidence of cancer screening for breast, cervical, prostate, and colorectal cancer in patients with rheumatoid arthritis. J. Rheumatol. 52, 988\u2013996 (2025).","journal-title":"J. Rheumatol."},{"key":"1386_CR83","doi-asserted-by":"publisher","unstructured":"McDermott, G. C. et al. Detection of lung abnormalities in patients with rheumatoid arthritis who smoke and who were screened for lung cancer with low-dose chest computed tomography imaging in routine clinical care: results from a large multihospital system. Arthritis Care Res. https:\/\/doi.org\/10.1002\/acr.25680 (2025).","DOI":"10.1002\/acr.25680"},{"key":"1386_CR84","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.jaad.2022.11.043","volume":"88","author":"MA Kreher","year":"2023","unstructured":"Kreher, M. A., Konda, S., Noland, M. M. B., Longo, M. I. & Valdes-Rodriguez, R. Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, Part II: methotrexate, alkylating agents, biologics, and small molecule inhibitors. J. Am. Acad. Dermatol. 88, 534\u2013542 (2023).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1386_CR85","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1093\/rheumatology\/keae275","volume":"63","author":"K Jatuworapruk","year":"2024","unstructured":"Jatuworapruk, K. & Pongkulkiat, P. Staphylococcal osteoarticular infection is a major threat to the expanding population of rheumatoid arthritis in the elderly. Rheumatology 63, 2909\u20132910 (2024).","journal-title":"Rheumatology"},{"key":"1386_CR86","doi-asserted-by":"publisher","first-page":"5647","DOI":"10.1093\/rheumatology\/keaf312","volume":"64","author":"MA Adas","year":"2025","unstructured":"Adas, M. A. et al. Risk of infection in patients with early inflammatory arthritis: results from a large UK prospective observational cohort study. Rheumatology 64, 5647\u20135655 (2025).","journal-title":"Rheumatology"},{"key":"1386_CR87","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1080\/03009742.2022.2049057","volume":"52","author":"SS Dieperink","year":"2023","unstructured":"Dieperink, S. S. et al. Risk of Staphylococcus aureus bacteraemia in patients with rheumatoid arthritis and the effect of orthopaedic implants on the risk: a nationwide observational cohort study. Scand. J. Rheumatol. 52, 250\u2013258 (2023).","journal-title":"Scand. J. Rheumatol."},{"key":"1386_CR88","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1093\/rheumatology\/keae132","volume":"63","author":"SS Dieperink","year":"2024","unstructured":"Dieperink, S. S. et al. Rheumatoid arthritis and risk of osteoarticular infection and death following Staphylococcus aureus bacteraemia: a nationwide cohort study. Rheumatology 63, 2989\u20132996 (2024).","journal-title":"Rheumatology"},{"key":"1386_CR89","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3899\/jrheum.121075","volume":"40","author":"OM Ni Mhuircheartaigh","year":"2013","unstructured":"Ni Mhuircheartaigh, O. M., Matteson, E. L., Green, A. B. & Crowson, C. S. Trends in serious infections in rheumatoid arthritis. J. Rheumatol. 40, 611\u2013616 (2013).","journal-title":"J. Rheumatol."},{"key":"1386_CR90","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/6259010","volume":"2018","author":"K Ichinose","year":"2018","unstructured":"Ichinose, K. et al. Frequency of hospitalized infections is reduced in rheumatoid arthritis patients who received biological and targeted synthetic disease-modifying antirheumatic drugs after 2010. J. Immunol. Res. 2018, 6259010 (2018).","journal-title":"J. Immunol. Res."},{"key":"1386_CR91","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/1744666X.2019.1705785","volume":"16","author":"YM Chiu","year":"2020","unstructured":"Chiu, Y. M. & Chen, D. Y. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert Rev. Clin. Immunol. 16, 207\u2013228 (2020).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"1386_CR92","doi-asserted-by":"publisher","first-page":"vi37","DOI":"10.1093\/rheumatology\/kes283","volume":"51","author":"EM Ruderman","year":"2012","unstructured":"Ruderman, E. M. Overview of safety of non-biologic and biologic DMARDs. Rheumatology 51, vi37\u2013vi43 (2012).","journal-title":"Rheumatology"},{"key":"1386_CR93","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001235","volume":"7","author":"TR Riley","year":"2021","unstructured":"Riley, T. R. & George, M. D. Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis. RMD Open 7, e001235 (2021).","journal-title":"RMD Open"},{"key":"1386_CR94","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","volume":"58","author":"K Bechman","year":"2019","unstructured":"Bechman, K. et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology 58, 1755\u20131766 (2019).","journal-title":"Rheumatology"},{"key":"1386_CR95","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1136\/ard.2008.089276","volume":"69","author":"JD Greenberg","year":"2010","unstructured":"Greenberg, J. D. et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann. Rheum. Dis. 69, 380\u2013386 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"1386_CR96","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1136\/ard-2023-224116","volume":"82","author":"M Ostergaard","year":"2023","unstructured":"Ostergaard, M. et al. Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial. Ann. Rheum. Dis. 82, 1286\u20131295 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1386_CR97","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/rheumatology\/keab438","volume":"61","author":"C Rempenault","year":"2022","unstructured":"Rempenault, C. et al. Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept. Rheumatology 61, 953\u2013962 (2022).","journal-title":"Rheumatology"},{"key":"1386_CR98","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/acr.25045","volume":"75","author":"AR Bass","year":"2023","unstructured":"Bass, A. R. et al. 2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Care Res. 75, 449\u2013464 (2023).","journal-title":"Arthritis Care Res."},{"key":"1386_CR99","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002636","volume":"8","author":"SS Dieperink","year":"2022","unstructured":"Dieperink, S. S. et al. Antirheumatic treatment, disease activity and risk of Staphylococcus aureus bacteraemia in rheumatoid arthritis: a nationwide nested case-control study. RMD Open 8, e002636 (2022).","journal-title":"RMD Open"},{"key":"1386_CR100","doi-asserted-by":"publisher","first-page":"870","DOI":"10.7326\/M20-1594","volume":"173","author":"MD George","year":"2020","unstructured":"George, M. D. et al. Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis : a cohort study. Ann. Intern. Med. 173, 870\u2013878 (2020).","journal-title":"Ann. Intern. Med."},{"key":"1386_CR101","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3899\/jrheum.181376","volume":"47","author":"T Qendro","year":"2020","unstructured":"Qendro, T. et al. Suboptimal immunization coverage among Canadian rheumatology patients in routine clinical care. J. Rheumatol. 47, 770\u2013778 (2020).","journal-title":"J. Rheumatol."},{"key":"1386_CR102","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3899\/jrheum.2023-0867","volume":"51","author":"V Furer","year":"2024","unstructured":"Furer, V. et al. Real-world coverage with influenza, pneumococcal, and herpes zoster vaccines among patients with rheumatic diseases in a nationwide healthcare plan. J. Rheumatol. 51, 505\u2013516 (2024).","journal-title":"J. Rheumatol."},{"key":"1386_CR103","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","volume":"83","author":"European Association for the Study of the Liver.","year":"2025","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatitis B virus infection. J. Hepatol. 83, 502\u2013583 (2025).","journal-title":"J. Hepatol."},{"key":"1386_CR104","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault, N. A. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67, 1560\u20131599 (2018).","journal-title":"Hepatology"},{"key":"1386_CR105","doi-asserted-by":"publisher","first-page":"SI271","DOI":"10.1093\/rheumatology\/kead352","volume":"62","author":"J Majnik","year":"2023","unstructured":"Majnik, J. & Nagy, G. Viewpoint: could better understanding of risk factors for comorbidities pave the way towards personalized therapy in rheumatoid arthritis? Rheumatology 62, SI271\u2013SI273 (2023).","journal-title":"Rheumatology"},{"key":"1386_CR106","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S2215-0366(18)30255-4","volume":"6","author":"L Nerurkar","year":"2019","unstructured":"Nerurkar, L., Siebert, S., McInnes, I. B. & Cavanagh, J. Rheumatoid arthritis and depression: an inflammatory perspective. Lancet Psychiatry 6, 164\u2013173 (2019).","journal-title":"Lancet Psychiatry"},{"key":"1386_CR107","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s10067-022-06455-x","volume":"42","author":"S Fang","year":"2023","unstructured":"Fang, S. et al. Assessment of bidirectional relationships between depression and rheumatoid arthritis among adults: a two-sample Mendelian randomization study. Clin. Rheumatol. 42, 1039\u20131046 (2023).","journal-title":"Clin. Rheumatol."},{"key":"1386_CR108","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3899\/jrheum.2024-0165","volume":"52","author":"RE Giblon","year":"2025","unstructured":"Giblon, R. E. et al. Trends in anxiety and depression among individuals with rheumatoid arthritis: a population-based study. J. Rheumatol. 52, 210\u2013218 (2025).","journal-title":"J. Rheumatol."},{"key":"1386_CR109","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/acr.23539","volume":"70","author":"RA Marrie","year":"2018","unstructured":"Marrie, R. A. et al. Increased burden of psychiatric disorders in rheumatoid arthritis. Arthritis Care Res. 70, 970\u2013978 (2018).","journal-title":"Arthritis Care Res."},{"key":"1386_CR110","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.semarthrit.2019.08.006","volume":"50","author":"L Carpenter","year":"2020","unstructured":"Carpenter, L. et al. Secular changes in functional disability, pain, fatigue and mental well-being in early rheumatoid arthritis. A longitudinal meta-analysis. Semin. Arthritis Rheum. 50, 209\u2013219 (2020).","journal-title":"Semin. Arthritis Rheum."},{"key":"1386_CR111","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jad.2022.05.108","volume":"311","author":"CYH Ng","year":"2022","unstructured":"Ng, C. Y. H. et al. Elucidating a bidirectional association between rheumatoid arthritis and depression: a systematic review and meta-analysis. J. Affect. Disord. 311, 407\u2013415 (2022).","journal-title":"J. Affect. Disord."},{"key":"1386_CR112","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1177\/10600280211062271","volume":"56","author":"A Silva Almodovar","year":"2022","unstructured":"Silva Almodovar, A., Nguyen, D. & Nahata, M. C. Evidence needed for efficacy of antidepressant medications among patients with rheumatoid arthritis. Ann. Pharmacother. 56, 1065\u20131075 (2022).","journal-title":"Ann. Pharmacother."},{"key":"1386_CR113","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1007\/s00296-024-05728-9","volume":"44","author":"S Bekarissova","year":"2024","unstructured":"Bekarissova, S., Bekarisov, O. & Bekaryssova, D. An integrated approach to the treatment of rheumatic diseases: the role of psychological interventions. Rheumatol. Int. 44, 2727\u20132735 (2024).","journal-title":"Rheumatol. Int."},{"key":"1386_CR114","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1001\/jama.2023.9297","volume":"329","author":"US Preventive Services Task Force","year":"2023","unstructured":"US Preventive Services Task Force. Screening for depression and suicide risk in adults: US Preventive Services Task Force recommendation statement. JAMA 329, 2057\u20132067 (2023).","journal-title":"JAMA"},{"key":"1386_CR115","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1001\/jama.2023.9301","volume":"329","author":"US Preventive Services Task Force","year":"2023","unstructured":"US Preventive Services Task Force. Screening for anxiety disorders in adults: US Preventive Services Task Force recommendation statement. JAMA 329, 2163\u20132170 (2023).","journal-title":"JAMA"},{"key":"1386_CR116","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/acr.24467","volume":"73","author":"RM Morla","year":"2021","unstructured":"Morla, R. M., Li, T., Castrejon, I., Luta, G. & Pincus, T. Multidimensional health assessment questionnaire as an effective tool to screen for depression in routine rheumatology care. Arthritis Care Res. 73, 120\u2013129 (2021).","journal-title":"Arthritis Care Res."},{"key":"1386_CR117","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1007\/s00296-020-04593-6","volume":"40","author":"L Lindner","year":"2020","unstructured":"Lindner, L. et al. Osteoporosis in patients with rheumatoid arthritis: trends in the German National Database 2007\u20132017. Rheumatol. Int. 40, 2005\u20132012 (2020).","journal-title":"Rheumatol. Int."},{"key":"1386_CR118","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00774-025-01598-8","volume":"43","author":"T Furuya","year":"2025","unstructured":"Furuya, T., Inoue, E., Yamanaka, H., Harigai, M. & Tanaka, E. Increasing fracture incidence over 13 years in patients with rheumatoid arthritis from the IORRA cohort. J. Bone Min. Metab. 43, 411\u2013418 (2025).","journal-title":"J. Bone Min. Metab."},{"key":"1386_CR119","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/03009742.2019.1611918","volume":"48","author":"BM Nyhall-Wahlin","year":"2019","unstructured":"Nyhall-Wahlin, B. M., Ajeganova, S., Petersson, I. F. & Andersson, M. Increased risk of osteoporotic fractures in Swedish patients with rheumatoid arthritis despite early treatment with potent disease-modifying anti-rheumatic drugs: a prospective general population-matched cohort study. Scand. J. Rheumatol. 48, 431\u2013438 (2019).","journal-title":"Scand. J. Rheumatol."},{"key":"1386_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152219","volume":"61","author":"LP Crowson","year":"2023","unstructured":"Crowson, L. P. et al. Time trends in glucocorticoid use in rheumatoid arthritis during the biologics era: 1999\u20132018. Semin. Arthritis Rheum. 61, 152219 (2023).","journal-title":"Semin. Arthritis Rheum."},{"key":"1386_CR121","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann. Rheum. Dis. 82, 3\u201318 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1386_CR122","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel, L. et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 73, 924\u2013939 (2021).","journal-title":"Arthritis Care Res."},{"key":"1386_CR123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho, P. M. et al. American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis \u2014 2020 update. Endocr. Pract. 26, 1\u201346 (2020).","journal-title":"Endocr. Pract."},{"key":"1386_CR124","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1001\/jama.2024.27154","volume":"333","author":"US Preventive Services Task Force","year":"2025","unstructured":"US Preventive Services Task Force. Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement. JAMA 333, 498\u2013508 (2025).","journal-title":"JAMA"},{"key":"1386_CR125","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1002\/acr.25240","volume":"75","author":"MB Humphrey","year":"2023","unstructured":"Humphrey, M. B. et al. 2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 75, 2405\u20132419 (2023).","journal-title":"Arthritis Care Res."},{"key":"1386_CR126","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3390\/ph13090234","volume":"13","author":"T Salvatore","year":"2020","unstructured":"Salvatore, T. et al. Metformin: a potential therapeutic tool for rheumatologists. Pharmaceuticals 13, 234 (2020).","journal-title":"Pharmaceuticals"},{"key":"1386_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103414","volume":"153","author":"Y Yang","year":"2025","unstructured":"Yang, Y. et al. Exploring glucagon-like peptide-1 receptor agonists as potential disease-modifying agents in autoimmune diseases. J. Autoimmun. 153, 103414 (2025).","journal-title":"J. Autoimmun."},{"key":"1386_CR128","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001211","volume":"6","author":"TK Kvien","year":"2020","unstructured":"Kvien, T. K. et al. Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities. RMD Open 6, e001211 (2020).","journal-title":"RMD Open"},{"key":"1386_CR129","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1111\/jcpe.13826","volume":"50","author":"AI Bolstad","year":"2023","unstructured":"Bolstad, A. I., Fevang, B. S. & Lie, S. A. Increased risk of periodontitis in patients with rheumatoid arthritis: a nationwide register study in Norway. J. Clin. Periodontol. 50, 1022\u20131032 (2023).","journal-title":"J. Clin. Periodontol."},{"key":"1386_CR130","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1093\/rheumatology\/keab894","volume":"61","author":"K Hellgren","year":"2022","unstructured":"Hellgren, K. et al. Pregnancy outcomes in relation to disease activity and anti-rheumatic treatment strategies in women with rheumatoid arthritis: a matched cohort study from Sweden and Denmark. Rheumatology 61, 3711\u20133722 (2022).","journal-title":"Rheumatology"},{"key":"1386_CR131","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002445","volume":"8","author":"AEP Secher","year":"2022","unstructured":"Secher, A. E. P. et al. Risk of pre-eclampsia and impact of disease activity and antirheumatic treatment in women with rheumatoid arthritis, axial spondylarthritis and psoriatic arthritis: a collaborative matched cohort study from Sweden and Denmark. RMD Open 8, e002445 (2022).","journal-title":"RMD Open"},{"key":"1386_CR132","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1164\/rccm.202505-1054ST","volume":"211","author":"AJ Podolanczuk","year":"2025","unstructured":"Podolanczuk, A. J. et al. Approach to the evaluation and management of interstitial lung abnormalities: an official American Thoracic Society clinical statement. Am. J. Resp. Crit. Care Med. 211, 1132\u20131155 (2025).","journal-title":"Am. J. Resp. Crit. Care Med."},{"key":"1386_CR133","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1136\/annrheumdis-2016-209233","volume":"75","author":"A Baillet","year":"2016","unstructured":"Baillet, A. et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. Ann. Rheum. Dis. 75, 965\u2013973 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1386_CR134","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.3899\/jrheum.141603","volume":"42","author":"CE Barber","year":"2015","unstructured":"Barber, C. E. et al. Development of cardiovascular quality indicators for rheumatoid arthritis: results from an international expert panel using a novel online process. J. Rheumatol. 42, 1548\u20131555 (2015).","journal-title":"J. Rheumatol."},{"key":"1386_CR135","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","volume":"79","author":"V Furer","year":"2020","unstructured":"Furer, V. et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann. Rheum. Dis. 79, 39\u201352 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1386_CR136","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.semarthrit.2020.09.016","volume":"51","author":"DL Conn","year":"2021","unstructured":"Conn, D. L. The story behind the use of glucocorticoids in the treatment of rheumatoid arthritis. Semin. Arthritis Rheum. 51, 15\u201319 (2021).","journal-title":"Semin. Arthritis Rheum."},{"key":"1386_CR137","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.jacc.2018.06.036","volume":"72","author":"S Kalkhoran","year":"2018","unstructured":"Kalkhoran, S., Benowitz, N. L. & Rigotti, N. A. Prevention and treatment of tobacco use: JACC Health Promotion Series. J. Am. Coll. Cardiol. 72, 1030\u20131045 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1386_CR138","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S0140-6736(11)60813-1","volume":"378","author":"BA Swinburn","year":"2011","unstructured":"Swinburn, B. A. et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet 378, 804\u2013814 (2011).","journal-title":"Lancet"},{"key":"1386_CR139","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","volume":"16","author":"BN Cronstein","year":"2020","unstructured":"Cronstein, B. N. & Aune, T. M. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat. Rev. Rheumatol. 16, 145\u2013154 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1386_CR140","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41584-023-01036-x","volume":"19","author":"M Feldmann","year":"2023","unstructured":"Feldmann, M., Maini, R. N., Soriano, E. R., Strand, V. & Takeuchi, T. 25 years of biologic DMARDs in rheumatology. Nat. Rev. Rheumatol. 19, 761\u2013766 (2023).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1386_CR141","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/ard.2009.123919","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen, J. S. et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 69, 631\u2013637 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"1386_CR142","unstructured":"Stewart, J. What are the new drugs for rheumatoid arthritis (RA)? Drugs.com https:\/\/www.drugs.com\/medical-answers\/new-drugs-treatment-rheumatoid-arthritis-3512243\/ (2025)."},{"key":"1386_CR143","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","volume":"389","author":"GR Burmester","year":"2017","unstructured":"Burmester, G. R. & Pope, J. E. Novel treatment strategies in rheumatoid arthritis. Lancet 389, 2338\u20132348 (2017).","journal-title":"Lancet"}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01386-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01386-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01386-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:02:29Z","timestamp":1782432149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01386-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":143,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1386"],"URL":"https:\/\/doi.org\/10.1038\/s41584-026-01386-2","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"8 May 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.R.E. received research support from, and served as a consultant for, Boehringer-Ingelheim, and has consulted for Artive Biotherapeutics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}